Short Interest in Interpace Biosciences, Inc. (OTCMKTS:IDXG) Decreases By 77.9%

Interpace Biosciences, Inc. (OTCMKTS:IDXG) was the target of a large decrease in short interest in April. As of April 30th, there was short interest totaling 616 shares, a decrease of 77.9% from the April 15th total of 2,793 shares. Based on an average daily trading volume, of 10,517 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.

Interpace Biosciences Trading Down 5.0%

IDXG stock traded down $0.10 during trading on Wednesday, hitting $1.90. The company had a trading volume of 7,825 shares, compared to its average volume of 8,441. The company has a fifty day moving average price of $1.90 and a two-hundred day moving average price of $1.52. The company has a market cap of $8.42 million, a P/E ratio of -95.00 and a beta of 0.65. Interpace Biosciences has a fifty-two week low of $0.70 and a fifty-two week high of $2.40.

Interpace Biosciences (OTCMKTS:IDXG) last released its quarterly earnings data on Tuesday, May 12th. The business services provider reported $0.03 earnings per share (EPS) for the quarter. The firm had revenue of $9.03 million during the quarter. Interpace Biosciences had a return on equity of 493.02% and a net margin of 63.46%.

About Interpace Biosciences

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.